Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metoprolol + amlodipine is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of hypertension (high blood pressure) and angina pectoris (chest pain). Metoprolol is a beta-blocker that selectively blocks beta1 adrenergic receptor in the heart, reducing heart rate and cardiac output. Amlodipine is a calcium channel blocker that inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Together, these drugs lower blood pressure more effectively than either agent alone, improve treatment adherence by combining two medications into one pill, and reduce the risk of cardiovascular events such as stroke or heart attack[1][3][4][5]. The combination has been shown to be safe, well-tolerated, and effective in clinical studies[3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metoprolol + amlodipine.